 <h1>Mycobutin Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>rifabutin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about rifabutin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Mycobutin.</p><h2>In Summary</h2><p><b>Common side effects of Mycobutin include:</b> neutropenia and urine discoloration.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to rifabutin: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, rifabutin (the active ingredient contained in Mycobutin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking rifabutin:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>fever</li>
<li>heartburn</li>
<li>indigestion</li>
<li>itching or skin rash</li>
<li>loss of appetite</li>
<li>painful or difficult urination</li>
<li>sore throat</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Loss of strength or energy</li>
<li>muscle pain</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bruising or purple spots on the skin</li>
<li>change in taste</li>
<li>eye pain</li>
<li>joint pain</li>
<li>loss of vision</li>
<li>lower back or side pain</li>
<li>muscle swelling or pain</li>
<li>pale skin</li>
<li>yellow skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of rifabutin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>bad, unusual, or unpleasant (after) taste in the mouth</li>
<li>belching</li>
<li>bloated or full feeling</li>
<li>change in taste</li>
<li>discoloration of the urine</li>
<li>excess air or gas in the stomach or intestines</li>
<li>headache</li>
<li>nausea</li>
<li>passing gas</li>
<li>trouble sleeping</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to rifabutin: oral capsule</i></p><h3>General</h3><p>The most commonly reported side effects included discolored urine, neutropenia, leukopenia, and jaundice.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Discolored urine (up to 30%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p>The frequency and severity of hematological side effects may be increased with concomitant isoniazid use.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Neutropenia (up to 25%), leukopenia (up to 17%)</p>
<p><b>Common</b> (1% to 10%): Anemia, eosinophilia, thrombocytopenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Agranulocytosis, granulocytopenia, lymphopenia, neutrophil count decreased, pancytopenia, platelet count decreased, white blood cell count decreased</p>
<p><b>Frequency not reported</b>: hemolysis, thrombotic thrombocytopenic purpura, white blood cell disorder<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Jaundice (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Increased alkaline phosphatase, increased ALT, increased AST</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatic enzymes increased</p>
<p><b>Frequency not reported</b>: Hepatitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 11%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Skin discoloration</p>
<p><b>Postmarketing reports</b>: Urticaria<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, dyspepsia, eructation, flatulence, gastrointestinal intolerance, nausea, nausea and vomiting, vomiting</p>
<p><b>Frequency not reported</b>: Clostridium difficile colitis</p>
<p><b>Postmarketing reports</b>: C difficile-associated diarrhea<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, fever, pain, pyrexia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, taste perversion</p>
<p><b>Frequency not reported</b>: aphasia, paresthesia, seizure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Generalized arthralgia occurred in patients given 1050 to 2400 mg/day; symptoms abated when treatment was discontinued.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Myalgia</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthralgia</p>
<p><b>Frequency not reported</b>: Myositis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain</p>
<p><b>Frequency not reported</b>: Chest pressure, nonspecific T wave changes (on ECG), shock</p>
<p><b>Postmarketing reports</b>: Hypotension<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p>
<p><b>Frequency not reported</b>: Confusion<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity, other hypersensitivity reactions</p>
<p><b>Frequency not reported</b>: Anaphylactic shock</p>
<p><b>Postmarketing reports</b>: Angioedema<sup>[Ref]</sup></p><h3>Ocular</h3><p>Uveitis occurred in patients given 1050 to 2400 mg/day; symptoms abated when treatment was discontinued.</p>
<p></p>
<p>Uveitis was rare when this drug was used as a single agent at 300 mg/day, or in combination with fluconazole and/or macrolides (e.g., clarithromycin).  However, the incidence of uveitis was greater if higher doses of this drug were used with these agents.  Patients who developed uveitis had mild to severe symptoms that resolved following therapy with corticosteroids and/or mydriatic eye drops; however, in some severe cases, resolution of symptoms occurred after several weeks.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Corneal deposits, uveitis</p>
<p><b>Postmarketing reports</b>: Conjunctivitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Bronchospasm</p>
<p><b>Frequency not reported</b>: Dyspnea<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Flu-like syndrome<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Mycobutin (rifabutin)." Pharmacia and Upjohn, Kalamazoo, MI. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Mycobutin (rifabutin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Generic Availability</li>
<li>Drug class: rifamycin derivatives</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Mycobutin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Mycobacterium avium-intracellulare, Treatment</li>
<li>Mycobacterium avium-intracellulare, Prophylaxis</li>
<li>Tuberculosis, HIV Positive</li>
<li>Tuberculosis, Prophylaxis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to rifabutin: oral capsule</i></p><h3>General</h3><p>The most commonly reported side effects included discolored urine, neutropenia, leukopenia, and jaundice.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Discolored urine (up to 30%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p>The frequency and severity of hematological side effects may be increased with concomitant isoniazid use.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Neutropenia (up to 25%), leukopenia (up to 17%)</p><p><b>Common</b> (1% to 10%): Anemia, eosinophilia, thrombocytopenia</p><p><b>Uncommon</b> (0.1% to 1%): Agranulocytosis, granulocytopenia, lymphopenia, neutrophil count decreased, pancytopenia, platelet count decreased, white blood cell count decreased</p><p><b>Frequency not reported</b>: hemolysis, thrombotic thrombocytopenic purpura, white blood cell disorder<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Jaundice (up to 12%)</p><p><b>Common</b> (1% to 10%): Increased alkaline phosphatase, increased ALT, increased AST</p><p><b>Uncommon</b> (0.1% to 1%): Hepatic enzymes increased</p><p><b>Frequency not reported</b>: Hepatitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 11%)</p><p><b>Uncommon</b> (0.1% to 1%): Skin discoloration</p><p><b>Postmarketing reports</b>: Urticaria<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, dyspepsia, eructation, flatulence, gastrointestinal intolerance, nausea, nausea and vomiting, vomiting</p><p><b>Frequency not reported</b>: Clostridium difficile colitis</p><p><b>Postmarketing reports</b>: C difficile-associated diarrhea<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, fever, pain, pyrexia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, taste perversion</p><p><b>Frequency not reported</b>: aphasia, paresthesia, seizure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Generalized arthralgia occurred in patients given 1050 to 2400 mg/day; symptoms abated when treatment was discontinued.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Myalgia</p><p><b>Uncommon</b> (0.1% to 1%): Arthralgia</p><p><b>Frequency not reported</b>: Myositis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain</p><p><b>Frequency not reported</b>: Chest pressure, nonspecific T wave changes (on ECG), shock</p><p><b>Postmarketing reports</b>: Hypotension<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><p><b>Frequency not reported</b>: Confusion<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity, other hypersensitivity reactions</p><p><b>Frequency not reported</b>: Anaphylactic shock</p><p><b>Postmarketing reports</b>: Angioedema<sup>[Ref]</sup></p><h3>Ocular</h3><p>Uveitis occurred in patients given 1050 to 2400 mg/day; symptoms abated when treatment was discontinued.</p><p></p><p>Uveitis was rare when this drug was used as a single agent at 300 mg/day, or in combination with fluconazole and/or macrolides (e.g., clarithromycin).  However, the incidence of uveitis was greater if higher doses of this drug were used with these agents.  Patients who developed uveitis had mild to severe symptoms that resolved following therapy with corticosteroids and/or mydriatic eye drops; however, in some severe cases, resolution of symptoms occurred after several weeks.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Corneal deposits, uveitis</p><p><b>Postmarketing reports</b>: Conjunctivitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Bronchospasm</p><p><b>Frequency not reported</b>: Dyspnea<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Flu-like syndrome<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Mycobutin (rifabutin)." Pharmacia and Upjohn, Kalamazoo, MI. </p><h2>More about Mycobutin (rifabutin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Generic Availability</li>
<li>Drug class: rifamycin derivatives</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Mycobutin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Mycobacterium avium-intracellulare, Treatment</li>
<li>Mycobacterium avium-intracellulare, Prophylaxis</li>
<li>Tuberculosis, HIV Positive</li>
<li>Tuberculosis, Prophylaxis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>